New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
06:09 EDTSGYPSynergy Pharmaceuticals to start second phase 3 clinical trial for plecanatide
Synergy Pharmaceuticals announced the start of its second pivotal phase 3 clinical trial to confirm the safety and efficacy of plecanatide, its lead uroguanylin analog and once-daily oral treatment, in adult patients with chronic idiopathic constipation, or CIC. This phase 3 trial is a randomized, double-blind clinical trial to compare a 12-week, dose-ranging regimen of plecanatide against placebo in adult patients with CIC.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
17:18 EDTSGYPSynergy Pharmaceuticals files $250M mixed securities shelf
Subscribe for More Information
June 24, 2015
05:59 EDTSGYPStocks with implied volatility below IV index mean; SGYP WMB
Subscribe for More Information
June 23, 2015
10:30 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information
09:14 EDTSGYPOn The Fly: Pre-market Movers
Subscribe for More Information
06:36 EDTSGYPSynergy Pharmaceuticals volatility elevated
Subscribe for More Information
06:02 EDTSGYPSynergy Pharma begins second of two Phase 3 clinical trials of plecanatide
Synergy Pharmaceuticals announced the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses, taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation, or IBS-C. The phase 3 IBS-C program includes two randomized, 12-week, double-blind, placebo-controlled pivotal trials conducted in the U.S. and each trial is expected to enroll approximately 1050 adult patients with IBS-C.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use